In 2013, two independent research groups described a novel antibody in sporadic inclusion body myositis (IBM): anti-cytosolic 5′-nucleotidase 1A (anti-cN-1A; anti-NT5C1A) (1, 2). Here, NT5C1A is linked to inclusion body myositis.